FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
What happened
FDA reviewed records Chengdu Innovation submitted after an April 29, 2024 request for records under section 704(a)(4). It found the company did not test the identity of each lot of incoming production material before release and its quality unit did not set up a system to approve or reject incoming materials. FDA placed the firm’s products on Import Alert 66-40 (a list that blocks imports) on January 17, 2025.
What FDA found
The company did not test the identity of each lot of incoming production material before releasing it for use.
The quality unit did not establish a system to approve or reject raw materials, intermediates, packaging, and labeling materials.
FDA said the APIs are adulterated because the firm’s methods, facilities, or controls do not conform to CGMP.
FD&C Act section 501(a)(2)(B)
What FDA wants
FDA tells the company to respond in writing within 30 working days with corrective actions and steps to prevent recurrence, including plans to test incoming material identity and strengthen quality unit oversight. If it cannot complete corrective actions within 15 working days, it must state why and give a completion schedule.
Who should pay attention
- drugmakers that use this firm's APIs
- companies relying on supplier certificates of analysis
- US applicants listing this site as an API manufacturer
This is a summary. Read the original letter on fda.gov.